Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application

Actinium Pharmaceuticals allowed key claims in a cornerstone patent application for treatment of metastatic solid cancers with alpha emitting isotopes

News provided by

Actinium Pharmaceuticals, Inc.

May 13, 2013, 06:00 ET

NEW YORK, May 13, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the U.S. Patent and Trademark Office (USPTO) has allowed a key patent application in the Company's portfolio. The patent application "Alpha Emitting Constructs and Uses Thereof" is licensed by Actinium Pharmaceuticals from Memorial Sloan Kettering Cancer Center (MSKCC).

The application covers treatment of metastatic solid cancers by targeting either cancer cells directly or blood vessels that provide for their growth with appropriate carriers of alpha emitting isotopes actinium 225 and bismuth 213. This technology allows Actinium Pharmaceuticals to expand use of its platform beyond blood borne and bone marrow located cancers, thus potentially offering broad categories of severely ill patients an efficacious therapy with a safety profile that could allow treatment of such patients. The patent is expected to issue in the next few months. Actinium Pharmaceuticals retains an exclusive license to use, develop, and commercialize this patent.

Dragan Cicic, MD, CMO of Actinium Pharmaceuticals, said: "This decision is an important step towards our goal of expanding the use of our technology to address the vast unmet medical need area of metastatic cancers in older patients. We have the potential to not only improve efficacy of cancer treatment but also enable it in many patients too sick to withstand the rigors of currently available therapies."

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or Contact:

Segio Traversa, CEO
Actinium Pharmaceuticals Inc.
E-mail: [email protected]

Media:
Dennis S. Dobson Jr., 203-258-0159
Email: [email protected]
www.dobsonmediagroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.